- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
North Chicago Today
By the People, for the People
Compagnie Lombard Odier SCmA Increases AbbVie Holdings
The institutional investor added over 16,000 shares of the pharmaceutical company's stock in Q4 2025.
Apr. 2, 2026 at 8:34am
Got story updates? Submit your updates here. ›
Compagnie Lombard Odier SCmA, an institutional investor, increased its position in AbbVie Inc. (NYSE:ABBV) by 5.3% during the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 322,464 shares of the pharmaceutical company's stock, valued at $73.68 million.
Why it matters
This transaction reflects Compagnie Lombard Odier SCmA's continued confidence in AbbVie's long-term growth potential. As a major institutional investor, the firm's portfolio moves can provide insights into broader market trends and investor sentiment around the pharmaceutical industry.
The details
Compagnie Lombard Odier SCmA purchased an additional 16,262 shares of AbbVie stock during the fourth quarter, bringing its total holdings to 322,464 shares. This represents a 5.3% increase in the firm's position compared to the prior quarter. AbbVie's stock price closed the year at $230 per share.
- Compagnie Lombard Odier SCmA filed its 13F report for the fourth quarter of 2025 on April 2, 2026.
- The 13F filing covers the period from October 1, 2025 to December 31, 2025.
The players
Compagnie Lombard Odier SCmA
An institutional investor and asset management firm based in Switzerland.
AbbVie Inc.
A global biopharmaceutical company that focuses on developing and commercializing therapies for complex and chronic medical conditions.
The takeaway
Compagnie Lombard Odier SCmA's increased stake in AbbVie suggests the firm sees continued growth potential in the pharmaceutical company's portfolio of specialty medicines and pipeline of new drug candidates. This transaction reflects broader investor confidence in the pharmaceutical industry's ability to navigate market challenges and deliver long-term value.
